The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 44000
Inclusion Criteria
- Patients must have at least one inpatient, or one physician office visit, emergency room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on the index date or during the pre-index period;
- Patients must be treatment naive from all OAC use prior to first dabigatran or warfarin prescription;
- Patients must be continuously enrolled in a health plan during the pre-index period;
- ...
- Patients must have at least one inpatient, or one physician office visit, emergency room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on the index date or during the pre-index period;
- Patients must be treatment naive from all OAC use prior to first dabigatran or warfarin prescription;
- Patients must be continuously enrolled in a health plan during the pre-index period;
- Aged 18-89 on the index date;
- Patients must have a prescription for dabigatran or warfarin (this first prescription will be the index date);
Exclusion Criteria
- Patients with valvular procedures related to the baseline AF diagnosis will be excluded;
- Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery, pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first diagnosis of AF;
- Patients with valvular procedures related to the baseline AF diagnosis will be excluded;
- Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery, pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first diagnosis of AF;
Summary
- Conditions
- Atrial Fibrillation
- Type
- Observational
- Design
- Time Perspective: Retrospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Study Design: Retrospective
Study Design: Retrospective
Inclusion Criteria
- Patients must have at least one inpatient, or one physician office visit, emergency room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on the index date or during the pre-index period;
- Patients must be treatment naive from all OAC use prior to first dabigatran or warfarin prescription;
- Patients must be continuously enrolled in a health plan during the pre-index period;
- ...
- Patients must have at least one inpatient, or one physician office visit, emergency room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on the index date or during the pre-index period;
- Patients must be treatment naive from all OAC use prior to first dabigatran or warfarin prescription;
- Patients must be continuously enrolled in a health plan during the pre-index period;
- Aged 18-89 on the index date;
- Patients must have a prescription for dabigatran or warfarin (this first prescription will be the index date);
Exclusion Criteria
- Patients with valvular procedures related to the baseline AF diagnosis will be excluded;
- Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery, pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first diagnosis of AF;
- Patients with valvular procedures related to the baseline AF diagnosis will be excluded;
- Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery, pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first diagnosis of AF;
Tracking Information
- NCT #
- NCT02043808
- Collaborators
- Not Provided
- Investigators
- Study Chair: Boehringer Ingelheim Boehringer Ingelheim